Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, announced that Michael W. Kent, M.D.,...
Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, announced that data demonstrating the...
Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, announced that the company will participate...
Aruvant Sciences ("Aruvant"), a clinical-stage biopharmaceutical company focused on developing and commercializing transformative gene therapies for...
Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercializing transformative gene therapies for the treatment of rare ...
Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, announced the appointment of Moya M. Daniels...
Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, announced that an abstract demonstrating the...
Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, announced an oral presentation at the Society ...
Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, today announced that members of the Aruvant leadership...
Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, today announced that data on ARU-2801, a potentially...
Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, today announced the appointment of Stanley J. Musial as...
Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, and Aldevron, the leading provider of high-quality...
Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, announced today two publications of data on...
Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, today announced that data on ARU-1801, a...
Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, today announced the selection of an abstract...
Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, announced it has added eleven scientists to...
Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, today announced the appointment of Meghan...
Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, today announced that the European Medicines Agency (EMA)...
Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, and Lonza announced today their agreement in support of...
Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, announced new data demonstrating the potentially curative ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.